Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Finance Watch: Investors Go Nuts For NASH As Madrigal Raises $300m, Galmed Skyrockets

Jun 15 2018

• By Mandy Jackson

Finance Watch

Related Content

NASH Drug Cost Concerns On Level With HCV Treatments For Payers

Apr 20 2016

Endpoint Selection Could Help Determine The NASH Race

Nov 21 2016

Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk

Mar 22 2017

Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie

Sep 06 2017

Intercept skyrockets 281% on NASH results

Jan 10 2014

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

May 25 2018

Pipeline Watch: Phase III Progress With Bempedoic Acid, Lefamulin, And Ibrutinib Combo

May 25 2018

Pipeline Watch: Phase III Progress With Burosumab, Duvelisib And Galcanezumab

May 18 2018

Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US

May 27 2018

IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose

Jan 04 2018

Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year

Apr 15 2018

Pipeline Watch: Phase III Starts With VX-445, Reproxalap And AVXS-101

Apr 27 2018

Deal Watch: Allergan, Celgene, AstraZeneca Among Biopharmas Advancing Existing Partnerships

May 24 2018

Deal Watch: Novo’s Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina

May 16 2018

Madrigal May Shake Up NASH Race With Phase II Resolution Data

May 31 2018

Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend

Feb 05 2018

Galmed To Design Phase III NASH Trial With FDA After Strong Aramchol Data

Jun 14 2018

IPO Update: Returns Rebound As June Sees Its First New Biopharma Offering

Jun 08 2018

Is Imfinzi The Culprit As Advaxis Combo Trial Goes On Hold After Death?

Mar 13 2018

Related Companies

Madrigal Pharmaceuticals, Inc.

Galmed Pharmaceuticals Ltd.

Intercept Pharmaceuticals, Inc.

Merck & Co., Inc.

Deciphera Pharmaceuticals, Inc.

ImmunoGen, Inc.

Mirati Therapeutics, Inc.

Bristol Myers Squibb Company

AstraZeneca PLC

Zymeworks, Inc.

Daiichi Sankyo Co., Ltd.

Marker Therapeutics, Inc.

Marker Therapeutics, Inc.

Viking Therapeutics, Inc.

Verrica Pharmaceuticals, Inc.

OptiNose, Inc.

Sesen Bio, Inc.

Verastem, Inc.

Infinity Pharmaceuticals, Inc.

AbbVie Inc.

Resverlogix Corporation

Advaxis, Inc.

FLEX Company

Additional Topics

Financing Business Strategies Clinical Trials Commercial Liver & Hepatic BioPharmaceutical

More from Financing

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window